Technologies
Ivermectin and COVID-19: Why poison centers are getting calls about this controversial drug
Is this a miracle pill or a sham?
Since the start of the COVID-19 pandemic, some medical professionals have reviewed already available drugs to see if they could be used as effective treatments. Ivermectin, an anti-parasitic, was administered to some patients across the globe, with seemingly positive effects. However, more studies show it has little to no effect when it comes to treating COVID-19. There’s also been an increase in calls to poison centers by people who are taking ivermectin intended for animals.
On one side, there are doctors who say ivermectin could help end the pandemic if used globally. On the other are public health officials who have reviewed the data and say the drug’s effectiveness against COVID-19 isn’t conclusive.
Here’s everything you need to know about ivermectin and its use for COVID-19.
What is ivermectin?
Ivermectin is an anti-parasitic medicine «that works by altering cellular channels,» said Dr. Soumi Eachempati, CEO of Cleared4 and former professor of surgery and public health at Weill Cornell Medical College. The drug inhibits some viruses from infecting cells, thus preventing the virus from spreading. Ivermectin is usually given to treat parasitic infections like lice and Strongyloides, according to Eachempati.
Scientists at pharmaceuticals giant Merck discovered ivermectin in 1975 and began to use it to treat scabies, river blindness and other parasitic diseases carried by worms and lice starting in 1981. It’s on the World Health Organization’s list of essential medicines for a basic health care system. More than 250 million people take the drug across the globe each year, and it’s effective for animals as well.
The drug is considered safe when taken in appropriate dosages. Side effects for the ivermectin vary depending on whether it’s taken orally to treat intestinal infections or topically for skin infections. Oral tablets can cause drowsiness, nausea, vomiting and, in very rare cases, an increase in heart rate and seizures. Side effects for the topical ivermectin can include skin rash and irritation, while dry skin and stinging pain are severe and rare.
Can ivermectin be used to cure COVID-19?
This is where things get complicated. Public health agencies, including the Federal Drug Administration, the National Institutes of Health and the World Health Organization, don’t suggest ivermectin’s use to treat COVID-19. They cite the lack of data from large, randomized trials confirming the drug’s effectiveness to treat the disease.
Doctors who cited multiple smaller studies and firsthand experience say otherwise. They claim ivermectin does work to prevent people from developing symptoms from COVID-19 and can shorten recovery time for those already infected.
What do the public health agencies say about ivermectin use for COVID-19 treatment?
The FDA said in March it hasn’t approved the use of ivermectin to treat COVID-19. It warned that large doses of the drug are «dangerous and can cause serious harm.» The agency also advised against human use of ivermectin produced for animals, such as cows and horses, as the doses aren’t the same and could contain ingredients intended only for animals.
A growing number of people have been taking ivermectin for animals as word’s spread on social media about its possible use against COVID-19. This has resulted in some people calling state poison centers after taking the drug, since the medication is intended for animals. On Aug. 20, the Mississippi State Department of Health sent out an alert regarding the number of calls its poison center received, with 70% related to the «ingestion of livestock or animal formulations of ivermectin purchased at livestock supply centers.»
In April, the FDA reaffirmed in a post on its website that ivermectin isn’t approved to treat COVID-19 nor has it been given emergency use authorization.
The NIH said in February there was insufficient data to «recommend either for or against the use of ivermectin for the treatment of COVID-19.» It did say lab tests found the drug stopped the reproduction of the SARS-CoV-2 virus that cause the disease. However, to be effective, the dosages would need to be «100-fold higher than those approved for use in humans.»
While some clinical studies showed ivermectin to have no benefit, the NIH said others saw a lower mortality rate among patients. However, those studies were incomplete or had methodological limitations such as small sample sizes or patients receiving additional medicine along with ivermectin, according to the NIH.
The WHO said in March the current evidence on the use of ivermectin for treatment of COVID-19 was «inconclusive.»
A doctor in Arkansas who prescribed the drug to patients is under investigation by the state medical board, according to a report from CNN. He reportedly gave ivermectin prescriptions to prisoners at the county jail where he was contracted to provide medical services.
Who says ivermectin is a treatment, and what information do they have?
Ivermectin’s potential use as a COVID-19 therapeutic made headway last December during a Senate Homeland Security Committee meeting called Focus on Early Treatment of COVID-19. Dr. Pierre Kory, a pulmonary and critical care specialist, testified about the drug’s usage for treatment of the disease.
«Ivermectin is highly safe, widely available, and low cost,» Kory said in the Senate meeting. «We now have data from over 20 well-designed clinical studies, 10 of them randomized, controlled trials, with every study consistently reporting large magnitude and statistically significant benefits in decreasing transmission rates, shortening recovery times, decreasing hospitalizations, or large reductions in deaths. These data show that ivermectin is effectively a ‘miracle drug’ against COVID-19.»
During his testimony, Kory referred to a paper he authored — Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 — that was published in the May edition of the American Journal of Therapeutics.
The paper was also included in the Frontiers of Pharmacology journal in January but was then removed in March. Dr. Frederick Fenter, chief executive editor of the journal, said the paper was removed due to «strong, unsupported claims based on studies with insufficient statistical significance, and at times, without the use of control groups.» Fender also said the authors promoted their own specific ivermectin-based treatment, which goes against editorial policies.
A study listed in Kory’s paper involved giving ivermectin to 234 uninfected health care workers in Argentina and found those who received the drug were far less likely to be diagnosed with COVID. For mildly ill patients, an Iraq study saw a quicker recovery time.
There are also studies that show otherwise. A clinical trial of 476 patients found ivermectin didn’t improve the recovery time in patients who had COVID-19. A review of 10 random clinical trials, with more than 1,000 participants, also didn’t find improvements with ivermectin. One Egyptian study claimed to show positive results, but it’s since been redacted over ethical concerns. Another study, of 1,500 patients, found that ivermectin had «no effect whatsoever.»
Merck, the company that discovered ivermectin, released a statement in February saying there was «no scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies» and «no meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease.» It also cited a lack of safety data from major studies.
Why is there controversy over ivermectin?
The debate about ivermectin’s usage to treat COVID-19 has gone from the hospital to social media, exacerbating the discourse as well as the vitriol. While those in support of the drug appear to want an end to the pandemic, their arguments in favor of ivermectin have become fodder for anti-vaxxers and conspiracy theorists.
Groups that have spread misinformation about COVID-19 throughout the pandemic latched onto ivermectin’s usage following Kory’s Senate testimony. Anti-vax groups on Telegram share misinformation about the vaccine while asking where they can buy the drug. Rumble, an alternative video platform to YouTube, has pages of videos falsely saying vaccines are ineffective while advising people to also take ivermectin.
Anti-vax posts and videos can also be found on YouTube, Facebook and Twitter, although the companies are attempting to take these posts down or make them harder to find.
Kory was a guest on the Dark Horse Podcast hosted by Bret Weinstein, a former professor at Evergreen State College, on June 1 to talk about ivermectin. That video was eventually demonetized on YouTube and Weinstein’s channel received a strike, which prevented him from posting content for one week and could lead to its removal if he receives two more strikes within 90 days.
YouTube says its actions on Weinstein’s videos were part of its policies.
«While we welcome open discussions of potential treatments and clinical trials related to COVID-19 on YouTube, based on guidance from the CDC, FDA and other local health authorities, we don’t currently allow content that recommends ivermectin as an effective treatment or prevention method for the virus,» said Ivy Choi, a YouTube spokesperson. «We craft our policies to prevent the risk of egregious real-world harm, and update them as official guidance evolves. We do allow exceptions to our policy about ivermectin, including content that also gives viewers the full context of the FDA’s current position.»
Because of YouTube’s decision, the controversy over ivermectin grew and became tied to what some claim to be «big tech censorship.»
What is required for ivermectin to get approved for COVID-19 treatment?
For the public health agencies, it’s going to come down to the results of large clinical studies being conducted around the world.
«In the UK, it was announced that ivermectin will be added to the Principle Trial, a large clinical study designed to assess potential COVID therapies for non-hospitalized therapies for patients at higher risk for severe disease,» said Dr. David Shafran, head of pediatrics at telehealth app K Health. «This should demonstrate more definitively the efficacy of ivermectin in early-stage COVID infections. Fingers crossed because it’s a cheap medication with a good safety profile. It would be great to add this to the armament of medication to fight COVID.»
The Oxford University Principle Trial has more than 5,000 participants and will give a three-day course of oral ivermectin treatment to individuals randomly and compare their results to individuals who will receive standard care.
In the US, the NIH is evaluating therapeutics for COVID-19 with its Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) master protocol. ivermectin was added in phase three of ACTIV-6, which will test the effectiveness of repurposed drugs.
«The ACTIV prioritization group, trial team and trial oversight groups continuously track new data on any agent we are studying in our trials and evaluate that data for how it might influence our testing of that agent and the safety/well being of the participants in the trial,» said Dr. Sarah Dunsmore, a program director at the National Center for Advancing Translational Sciences that is part of the NIH.
What’s unclear is how long the whole process will take. The studies need time to be completed, and then the agencies will require additional time to come up with decisions based on the data.
Technologies
Investors Favor Alphabet’s AI Spending Over Meta’s Despite Both Beating Earnings Expectations
Despite both Meta and Alphabet surpassing earnings expectations and raising AI spending forecasts, investors reacted differently, with Alphabet’s stock rising 7% while Meta’s fell 7%, highlighting the market’s preference for companies with cloud infrastructure that can monetize AI investments.
On Wednesday, both Meta and Alphabet surpassed analyst expectations in their quarterly earnings, marking their most robust growth in several years. The companies also raised their annual capital expenditure projections, signaling a continued commitment to investing heavily in artificial intelligence infrastructure.
However, Wall Street responded differently to the two tech giants. Alphabet’s stock surged 7% in after-hours trading, whereas Meta’s shares dropped by 7%.
This divergence continues a pattern that has weighed on Meta during much of the generative AI expansion. Unlike Alphabet, Microsoft, and Amazon, which operate vast cloud infrastructure businesses that convert AI investments into revenue, Meta lacks such a division.
Consequently, convincing investors of the return on AI spending is more challenging for Meta CEO Mark Zuckerberg, as the benefits must primarily manifest through higher ad revenue and improved profitability.
All four major tech firms released their quarterly results on Wednesday. While Alphabet, Microsoft, and Amazon reported cloud divisions that outperformed expectations, Meta was the only one among them to see its stock decline.
Leading up to the earnings releases, Alphabet’s stock had climbed 118% over the past year, significantly outpacing Meta’s 21% gain. Amazon rose 40%, and Microsoft increased by approximately 8%.
«Google is outperforming its peers which is well reflected in the current valuation,» analysts at D.A. Davidson wrote in a report after the results, maintaining their neutral rating.
The capital expenditure figures across the board are staggering and continue to grow, partly because companies are spending more on memory due to a global shortage driven by surging AI demand.
Alphabet updated its 2026 capex guidance range to $180 billion to $190 billion, up from its previous estimate of $175 billion to $185 billion. CFO Anat Ashkenazi said the company’s 2027 capex is expected to «significantly increase» from this year’s figure.
The spending forecast was coupled with revenue growth of 20%, the fastest for any quarter since 2022. Cloud revenue soared 63%, and Alphabet said it has a backlog of $460 billion, nearly double where it was last quarter, because of demand for AI infrastructure.
Defending the Spending
Meta upped its capex guidance for the year to between $125 billion and $145 billion, from a prior range of $115 billion to $135 billion, a move the company said, «reflects our expectations for higher component pricing this year and, to a lesser extent, additional data center costs to support future year capacity.»
Similar to when Meta raised its capex forecast in October, Zuckerberg spent time on the earnings call defending the company’s hefty AI spending, pitching it as necessary for future growth while bolstering the core online ad business.
«The trend over the last few years seems clear, that we are seeing an increasing return on the amount that we can improve engagement for people and value for advertisers,» Zuckerberg said. «This encourages us to continue investing heavily in what we expect will provide increasing value over the coming years as well.»
On the revenue side, growth is more impressive than at Google. Sales jumped 33% from a year earlier, marking the strongest period for expansion since 2021.
Zuckerberg said the company is «very focused on increasing the efficiency of our investments,» and is developing custom silicon with Broadcom while investing in a «significant amount of AMD chips to complement the new Nvidia systems that we’re rolling out as well.»
Meta CFO Susan Li told analysts that the company needs to spend big on AI in order to «meet our infrastructure needs and ensure we maximize our strategic flexibility over the coming years.» The company also has to ensure it has enough computing resources to train more AI models, build more products and help its AI agent push for consumers and businesses worldwide, Li said.
She added that Meta’s recent «multi-year cloud deals and our infrastructure purchase agreements» contributed to a $107 billion jump in contractual commitments during the quarter.
Still, investors are waiting to see new revenue streams come to fruition after Zuckerberg spent the past 10 months overhauling his company’s AI strategy and bringing in high-priced talent. Earlier this month, Meta debuted Muse Spark as its first proprietary foundation model.
Alphabet, meanwhile, has been cashing in on its bets, including on homegrown chips called tensor processing units (TPUs), which are increasingly competing with Nvidia’s graphics processing units (GPUs).
CEO Sundar Pichai addressed the momentum in the chip side of the business several times on Wednesday’s call.
«There’s tremendous demand for both AI solutions as well as AI infrastructure, including massive interest in our GPU offerings, as well as TPUs,» he said.
WATCH: Meta shares sliding
Technologies
Alphabet’s Q1 Earnings Expected to Reflect Sustained Expansion, Driven by Cloud Division
Alphabet’s Q1 earnings are expected to show strong growth driven by cloud and AI advancements, with revenue projected to rise 18.7% year-over-year. The company’s stock has surged 118% over the past year, supported by Gemini AI integration and expanding cloud infrastructure investments.
Alphabet is scheduled to release its first-quarter financial results after market close on Wednesday. Below are the key metrics Wall Street anticipates, based on analyst estimates from LSEG: — Earnings per share: $2.63 — Revenue: $107.2 billion Investors are also tracking several additional figures in the upcoming report: — Google Cloud: Estimated at $18.05 billion, per StreetAccount — YouTube advertising: Estimated at $9.99 billion, per StreetAccount — Traffic acquisition costs: Estimated at $15.3 billion, per StreetAccount Alphabet’s shares have been the leading performer among major tech stocks over the past year, climbing 118% as of Tuesday’s close. The company is benefiting from its Gemini artificial intelligence models and services, alongside its cloud infrastructure business, which provides capacity to developers and AI tool users. Analysts forecast an 18.7% increase in revenue from $90.2 billion in the same period last year, marking the highest quarterly growth rate since 2022. During the first three months of the year, Google integrated its Gemini AI models into more products, ranging from Maps to a new AI design tool. Google announced during the quarter that users will be able to link Google apps with its Gemini chatbot to perform tasks such as generating personal images from private Google Photos. Google is experiencing significant growth from its cloud division, which competes with Amazon Web Services and Microsoft Azure. Revenue is projected to surge 47% from $12.26 billion in the same quarter a year ago. Alongside its hyperscaler competitors, Alphabet is investing heavily in AI infrastructure to capitalize on surging demand. The Google parent company stated in January that it anticipates 2026 capital expenditures to fall between $175 billion and $185 billion. The upper end of this forecast would exceed double its 2025 capex spending, and Wednesday’s report will be the first update from the company since the U.S.-Iran conflict began in February, causing oil prices to spike. Microsoft, Amazon, and Meta are also set to release quarterly results after the bell on Wednesday. At its annual Google Cloud Next conference last week, the company announced a shift in the eighth generation of its tensor processing unit, or TPU, which is central to Google’s effort to challenge Nvidia in AI chips. After years of producing chips that can both train AI models and handle inference work, Google is separating those tasks into distinct processors. Alphabet’s investments may also be a focus for investors. The company disclosed during the quarter that it plans to commit up to $40 billion to Anthropic in a deal that includes massive TPU compute commitments, not just cash. Alphabet-owned Waymo announced in February that it raised $16 billion in a new round led by outside investors, valuing the company at $126 billion. Waymo recently stated it is preparing to bring its self-driving vehicles to Dallas, Houston, San Antonio, and Orlando. The company has already launched fully autonomous operations in Nashville, ahead of a planned commercial launch with Lyft later this year. The company also reduced some equity stakes. Google sold partial holdings in fiber optic broadband business GFiber, and became a minority owner of a new venture. Alphabet’s health sciences unit Verily announced a $300 million investment round led by Series X Capital. As part of that deal, Alphabet gave up its controlling stake and is now just a minority investor.
Technologies
Amazon to Release First-Quarter Financials Following Market Close
Amazon is set to release its first-quarter financial results after the market closes on Wednesday, with Wall Street anticipating a 14% revenue increase to $177.3 billion.
Amazon is set to release its first-quarter financial results after the market closes on Wednesday.
Here’s what Wall Street is anticipating, based on estimates compiled by LSEG:
— Earnings per share: $1.64
— Revenue: $177.3 billion
Wall Street is also tracking other key revenue figures:
— Amazon Web Services: $36.92 billion expected, according to StreetAccount
— Advertising: $16.87 billion expected, according to StreetAccount
Revenue is projected to increase 14% in the first quarter, an acceleration from a year earlier, when sales grew 8.6% to $155.7 billion, and roughly in line with last quarter’s 13.6% growth.
Investors will be closely watching Amazon’s cloud business, where revenue is expected to jump roughly 26% from a year ago. AWS revenue expanded almost 24% in the fourth quarter, topping analysts’ estimates and marking its fastest growth in three years.
Amazon and other big tech companies have been trying to justify their hefty artificial intelligence spending, which could approach $700 billion in 2026. Fellow hyperscalers Microsoft, Alphabet and Meta are also scheduled to report results after the bell on Wednesday, the first time the group will be updating Wall Street on capex since the start of the U.S.-Iran war in February.
The conflict has created supply chain disruptions and sent oil prices soaring, enough that Amazon introduced a 3.5% fuel surcharge for some of its third-party sellers.
Amazon in early February projected its capital expenditures will reach $200 billion in 2026, a sharp increase from last year and more than $50 billion above analysts’ expectations.
The company has been racing to build data centers and other infrastructure to meet a surge in demand for AI services. Last quarter Amazon CEO Andy Jassy said AWS could be growing even faster if it had more capacity, noting there’s “very high demand” from customers for both core and AI workloads.
Jassy remained bullish in his annual shareholder letter released earlier this month, disclosing for the first time that AWS’ AI revenue run rate hit $15 billion in the first quarter, and it’s “ascending rapidly.”
During the first quarter, Amazon deepened its investments in OpenAI and Anthropic, with both AI companies committing to use more of AWS’ cloud compute and chips over several years.
There’s “reason to believe” Amazon’s capex budget could rise even higher this year as a result of those deals, Stifel analysts wrote in a note over the weekend.
“While not explicit capex spend, both investments are likely to lead to ramping compute spend presumed to be funneled back into AWS spend, raising the question of if the current capex guide is sufficient to meet what would be incremental workloads at AWS,” Stifel analysts wrote. The firm has a buy rating on Amazon’s shares.
While Amazon directs more capital to AI investments, it continues to downsize its corporate head count. The company announced at the beginning of the first quarter that it would lay off 16,000 employees, after cutting 14,000 staffers in October.
Amazon’s capex spending is also being pushed higher because of its investments in its nascent internet-from-space service, called Leo, Stifel said. The company is aiming to begin commercial service in mid-2026.
Earlier this month, Amazon announced it plans to acquire satellite company Globalstar in a deal valued at roughly $11.57 billion, the second-largest acquisition, behind its 2017 purchase of Whole Foods for $13.7 billion.
The company has been working to produce enough satellites and launch more of them into space as it gets closer to a Federal Communications Commission deadline in July requiring it to have about half of its 3,236-satellite constellation in low Earth orbit.
Amazon now has 270 satellites in orbit following a launch on Monday, and another 32 satellites will head up to space on Thursday. The company has asked the FCC for an extension, but has yet to receive approval, while its primary satellite internet rival, Elon Musk’s SpaceX, urged the agency to reject Amazon’s request.
WATCH: Amazon needs to spend more to keep AWS as premier AI play
-
Technologies3 года agoTech Companies Need to Be Held Accountable for Security, Experts Say
-
Technologies3 года agoBest Handheld Game Console in 2023
-
Technologies3 года agoTighten Up Your VR Game With the Best Head Straps for Quest 2
-
Technologies4 года agoBlack Friday 2021: The best deals on TVs, headphones, kitchenware, and more
-
Technologies5 лет agoGoogle to require vaccinations as Silicon Valley rethinks return-to-office policies
-
Technologies5 лет agoVerum, Wickr and Threema: next generation secured messengers
-
Technologies4 года agoThe number of Сrypto Bank customers increased by 10% in five days
-
Technologies5 лет agoOlivia Harlan Dekker for Verum Messenger
